In some antiretroviral drug distribution programmes, free drugs are provided only, or preferentially, to patients who are treatment-naive. Colebunders and colleagues argue that such a restricted policy is highly problematic.
No takes yet. Share an insight, caveat, or question.
Colebunders et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: